AU4136901A - Novel methods for the treatment and prevention of dizziness and pruritus - Google Patents

Novel methods for the treatment and prevention of dizziness and pruritus

Info

Publication number
AU4136901A
AU4136901A AU41369/01A AU4136901A AU4136901A AU 4136901 A AU4136901 A AU 4136901A AU 41369/01 A AU41369/01 A AU 41369/01A AU 4136901 A AU4136901 A AU 4136901A AU 4136901 A AU4136901 A AU 4136901A
Authority
AU
Australia
Prior art keywords
pruritus
dizziness
prevention
treatment
novel methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41369/01A
Inventor
Randall L. Carpenter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adolor Corp
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of AU4136901A publication Critical patent/AU4136901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU41369/01A 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of dizziness and pruritus Abandoned AU4136901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45081299A 1999-11-29 1999-11-29
US09450812 1999-11-29
PCT/US2000/042310 WO2001041705A2 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of dizziness and pruritus

Publications (1)

Publication Number Publication Date
AU4136901A true AU4136901A (en) 2001-06-18

Family

ID=23789587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41369/01A Abandoned AU4136901A (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of dizziness and pruritus

Country Status (2)

Country Link
AU (1) AU4136901A (en)
WO (1) WO2001041705A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
SI2368553T1 (en) * 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
AU2013203378B2 (en) * 2003-04-08 2016-09-15 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (en) 2005-03-07 2019-05-27 Univ Chicago Use of opioid antagonists to attenuate the proliferation and migration of endothelial cells
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2423004T3 (en) * 2005-03-10 2013-09-17 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis  
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
EP2034977B1 (en) 2006-04-21 2011-07-13 DSM IP Assets B.V. Use of opioid receptor antagonists
MX2009010550A (en) 2007-03-29 2009-12-14 Progenics Pharm Inc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
EP3064503A1 (en) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PT2139890E (en) 2007-03-29 2014-09-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
WO2001041705A3 (en) 2001-12-20
WO2001041705A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2212299A (en) Compositions and methods for the treatment of tumor
AU4136901A (en) Novel methods for the treatment and prevention of dizziness and pruritus
AU3791601A (en) Treatment of coal
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU2469599A (en) Methods for the prevention and treatment of fibrosis and sclerosis
AU5042000A (en) Methods of treating proliferative disorders
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU1556497A (en) Agents for the treatment and prevention of aids
AU2001279958A1 (en) Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatorydisorders
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU3119100A (en) Methods for the prevention and treatment of post-surgical complications
AU2566201A (en) Compounds and methods for the treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
AU4751300A (en) Method and device for the continuous production of NaAlCl4 or NaFeCl4
AU4598400A (en) Method of treatment
AU3735900A (en) Methods of treatment and prevention of restenosis
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
AU1792200A (en) Use of phanquinone for the treatment or prevention of memory impairment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase